Date: February 12, 2026 Introduction ICON plc (NASDAQ: ICLR) currently finds itself at a pivotal and precarious crossroads. As the world’s second-largest Clinical Research Organization (CRO), the Dublin-headquartered giant has long been the backbone of global drug development, orchestrating the complex trials that bring life-saving therapies to market. However, as of February 2026, the company [...]
IQVIA’s fourth quarter was marked by solid top-line growth, surpassing Wall Street’s revenue expectations. However, the market reacted negatively, focusing on margin compression and concerns about the sustainability of recent gains. Management attributed the quarter’s performance to continued investments in clinical and commercial offerings, expansion of Phase I trial capabilities, and strong demand for its data-as-a-service solutions. CEO Ari Bousbib acknowledged that a challenging macroeconomic environment and slower customer decision-making, particularly in biotech, weighed on earlier results, while improved demand indicators became evident as the year progressed.
Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.
Shares of clinical research company IQVIA (NYSE: IQV)
fell 8.5% in the morning session after the company issued a weak full-year 2026 profit forecast that fell below Wall Street expectations.
Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
What a time it’s been for IQVIA. In the past six months alone, the company’s stock price has increased by a massive 51.4%, reaching $242.50 per share. This performance may have investors wondering how to approach the situation.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
In the complex ecosystem of modern medicine, few companies carry as much institutional weight—or stir as much controversy—as Charles River Laboratories International, Inc. (NYSE: CRL). As of December 23, 2025, Charles River stands as the indispensable backbone of the global pharmaceutical industry. It is a company that has, remarkably, participated in the development of over [...]
Artificial Intelligence (AI) stands at the precipice of revolutionizing healthcare, promising breakthroughs in diagnostics, personalized treatment, and operational efficiency. However, the path to widespread, ethical, and effective AI adoption in medical settings is fraught with significant challenges. As of December 12, 2025, the immediate significance of these hurdles—encompassing the critical need for trust, comprehensive clinician [...]
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
